Special Issue "Inhibitor of Growth (ING) Genes"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 August 2019

Special Issue Editor

Guest Editor
Dr. Rémy Pedeux

INSERM U1242 COSS laboratory, Universit é de Rennes-1, 35042 Rennes, France
Website | E-Mail
Interests: INhibitor or Growth genes, tumor suppressor genes, dna damage, dna repair, therapies; lung cancer; cell death; apoptosis; senescence; cell cycle

Special Issue Information

Dear Colleagues,

ING1 (Growth Inhibitor 1) was identified more than 20 years ago as a tumor suppressor gene. In the years that followed, it was revealed that ING1 belonged to a family of highly conserved proteins, both structurally and functionally, from yeast to human. In humans, there are 5 ING genes. Reports have shown that loss of expression of ING proteins is common in many tumor types. KO mice for ING1 or ING2 spontaneously develop tumors. Functionally, ING proteins are all involved in acetylation or deacetylation complexes and in chromatin remodeling. ING proteins have a PHD (Plant HomeoDomain) motif that has a strong affinity for the histone brand H3K4me3. Consequently, ING proteins are responsible for the targeting of histone acetylase or histone deacetylase complex to specific chromatin sites. ING proteins are involved in important functions such as cell cycle control, apoptosis and cellular senescence. The regulation of their functions remains little known; however, sumoylation of ING proteins appears to play an important role.

In this special issue, we will publish original journals and research that provide new insights into the role of ING genes in cancer. This will go from the mechanisms responsible for their loss of expression in human tumors to their functions in suppressive tumor signaling pathways and how these functions are regulated. Finally, information on how they can be used as markers or therapeutically targeted will be welcome.

Dr. Rémy Pedeux
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

This special issue is now open for submission.
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top